Evidence map›Paper›PMID 35702425›Full record

ArticleRSC advances2022

Versatile synthesis of pathogen specific bacterial cell wall building blocks.

Lukas Martin Wingen, Christina Braun, Marvin Rausch, Harald Gross, Tanja Schneider, Dirk Menche

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Lipid II unlocked: strategies for obtaining a major antibiotic target.Chemical communications (Cambridge, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lukas Martin WingenKekulé Institute of Organic Chemistry and Biochemistry, University of Bonn D-53121 Bonn Germany dirk.menche@uni-bonn.de.
Christina BraunKekulé Institute of Organic Chemistry and Biochemistry, University of Bonn D-53121 Bonn Germany dirk.menche@uni-bonn.de.
Marvin RauschInstitute for Pharmaceutical Microbiology, University Clinic Bonn, University of Bonn D-53115 Bonn Germany.
Harald GrossPharmaceutical Institute, Dept. of Pharmaceutical Biology, University of Tübingen D-72076 Tübingen Germany.ORCID https://orcid.org/0000-0002-0731-821X
Tanja SchneiderInstitute for Pharmaceutical Microbiology, University Clinic Bonn, University of Bonn D-53115 Bonn Germany.ORCID https://orcid.org/0000-0001-7269-4716
Dirk MencheKekulé Institute of Organic Chemistry and Biochemistry, University of Bonn D-53121 Bonn Germany dirk.menche@uni-bonn.de.ORCID https://orcid.org/0000-0002-4724-8383
University of Bonn · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Full details on the design, strategies and tactics for development of a novel synthetic sequence to farnesyl lipid I and II analogs is reported. The modular route was based on a three coupling strategy involving an efficient solid phase synthesis of the elaborate peptide fragment, which proceeded with excellent yield and stereoselectivity and was efficiently applied for the convergent synthesis of 3-lipid I and II. Furthermore, the generality of this route was demonstrated by synthesis of 3-lipid I congeners that are characteristic for

Identifiers

PMID35702425
PMCPMC9115884
OpenAlexW4282961788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.